- Global Pharma News & Resources

Tachyon Presents Preclinical Data on the Company’s Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting

HOUSTON--(BUSINESS WIRE)--Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Company’s first-in-class KDM4 inhibitor, at the American Association for Cancer Research ("AACR") Annual Meeting 2022. TACH101 is an investigational agent for the potential treatment of adult patients with diffuse large B-cell lymphoma (DLBCL).

“These preclinical data on TACH101 highlight its anti-tumor activity in DLBCL, the most common and aggressive type of non-Hodgkin lymphoma,” said Frank Perabo, M.D., Ph.D., CEO of Tachyon Therapuetics. “This work has increased our understanding of the potential for TACH101 in hematologic malignancies and also attests to its broad applicability in cancer, including solid tumors as was presented at AACR previously. We look forward to advancing TACH101 into clinical study.”

The data presented from both in vitro and in vivo preclinical studies demonstrated that targeting KDM4 with TACH101 resulted in significantly reduced growth of DLBCL cell lines representing the major DLBCL subtypes (GCB, ABC, and PMBL). Additionally, in vivo studies showed TACH101 treatment resulted in significant inhibition of tumor growth leading to complete remission in patient-derived xenograft models.

Highlights from the poster presentation (Poster #3720) are summarized below:

  • TACH101 showed potent anti-proliferative activity in DLBCL cell lines with IC50 as low as 0.01 µM.
  • Further evaluation demonstrated DLBCL cell lines were 100% sensitive to TACH101 treatment independent of their molecular subtype.
  • In vivo, TACH101 triggered effective tumor control (100%) in xenograft models of DLBCL (OCI-LY19).
  • TACH101 treatment caused downregulation of PNUTS gene expression. PNUTS is a direct target of KDM4 and can serve as a potential pharmacodynamic marker of TACH101 activity in clinical studies.
  • TACH101 demonstrated favorable pharmacologic and ADME profile without significant off-target activity and low probability of drug-drug interactions.

AACR 2022 is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022. The poster presentation titled, “TACH101, a First-in-Class Inhibitor of KDM4 Histone Lysine Demethylase for Treatment of Diffuse Large B-Cell Lymphoma,” will be available for viewing to registered attendees starting on Friday, April 8 at 1 pm ET through Wednesday, July 13 on the AACR Annual Meeting 2022 website. The poster will be presented on April 13 from 10am to 1:30pm ET in the session: PO.MCB05.04 – Chromatin Modifiers: Mutations and Novel Therapeutics.

About Tachyon Therapeutics Inc.

Tachyon Therapeutics, Inc. develops first-in-class therapeutics against novel targets from previously unexplored cancer dysregulation pathways to propel new options for the treatment of advanced cancers. Tachyon operates with a dedicated internal core development team and a virtual external network of expertise to achieve one goal – advance our programs with speed and innovation, without compromising the quality or integrity of our science. For more information, please visit


Investor & Company Contact: Frank Perabo, Chief Executive Officer, +1 (832) 952-0829,
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., +1 (858) 344-8091,

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Apr-2022